thermogenesis-based treatment of obesity and metabolic disorders
Equator Therapeutics did not materially change its thesis between March 31, 2022 and February 26, 2023. In both statements, the company says obesity and metabolic disorders need a third lever beyond diet and exercise: thermogenesis, the body's own heat production. The core claim stays the same all the way through: modern indoor comfort suppresses calorie-burning heat production, and drugging mitochondrial pathways could switch it back on. What changed is mostly emphasis and phrasing. The 2022 version leans a bit more on the historical story, humans once relied on thermogenesis to stay warm, and frames the idea as reactivating a natural process. The 2023 version sounds slightly tighter and more mechanistic: it stresses selective activation of mitochondrial thermogenic pathways and states the hoped-for outcomes more directly, sustained weight loss and reversal of metabolic disorders. The evidence base in these entries is thin. They read like a stable company belief, not a record of new clinical proof, target validation, or human outcomes. So the belief evolution here is small: same hypothesis, slightly sharper wording, and no visible shift in ambition or scope.